Abuse-deterrent extended-release oxycodone and risk of opioid-related harm.

ABSTRACT:

Aim

To establish and quantify the association between abuse-deterrent formulation (ADF) oxycodone and 1-year risk of opioid-related harm.

Design

Propensity score-matched cohort study of electronic medical records for years 2014-18, with patients followed up for 1 year after their index health-care visit.

Setting

More than 70 million patients from 56 US health-care organizations.

Participants

Patients aged 18-64 years at index health-care visit with any indication for an oral opioid analgesic, with no past 12-month history of oral oxycodone use or substance use disorder, and who were alive at the end of the 1-year follow-up (new episode of prescription oral ADF oxycodone [OxyContin], n = 45 045; new episode of non-ADF oxycodone opioid preparation, n = 1 377 359)

SUBMITTER: Paljarvi T 

PROVIDER: S-EPMC8363193 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature